STAAR Surgical Company (STAA)
NASDAQ: STAAHealth CareOphthalmic GoodsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
STAA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.22B
- P/E (TTM)
- 2,422.00
- Forward P/E
- 21.39
- EPS (TTM)
- $0.01
- Dividend yield
- None
- 52-week range
- 15.59 – 35.87
- Day range
- 23.87 – 25.08
- Volume / Avg
- 585.63K / 835.89K
- Beta
- —
- Shares outstanding
- 50.20M
52-week range
STAA stock today
On Nov 20, STAA ended the session at $24.22, shedding $0.81 (3.24%), versus the S&P 500's 3.70% decline. Shares are 32.5% below their 52-week high of $35.87, set on May 14, 2026 and 55.4% above the 52-week low of $15.59, in the middle of the past year's range. STAA is up 4.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.5%.
At 2,422x trailing earnings, STAAR Surgical's P/E ratio is unusually high because its trailing profit is very small relative to its share price.
Summary generated from market data by MetaCap's automated system. Methodology
About STAAR Surgical
Company profileSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists.
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- CEO
- Mr. Warren Foust
- Headquarters
- Lake Forest, CA
- Employees
- 921
- Website
- staar.com
Financial highlights
Full financialsIn fiscal 2025, STAAR Surgical generated $239.4 million in revenue, down 23.7% from fiscal 2024, its first annual decline since 2024. STAAR Surgical reported a net loss of $80.4 million, compared with a loss of $20.2 million a year earlier. Gross margin was 76.2% (down from 76.3%) and operating margin -38.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $239.44M | $313.90M | $322.42M | $239.44M | $230.47M |
| Growth | -23.72% | -2.64% | +34.65% | +3.89% | +41.00% |
| Net income | $-80.45M | $-20.21M | $21.35M | $39.66M | $27.51M |
| EPS (diluted) | $-1.62 | $-0.41 | $0.43 | $0.80 | $0.56 |
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$28.56+17.92%
- Strong buy 0
- Buy 4
- Hold 6
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.11 vs $0.05
- Surprise
- +120.00%
STAA news
All STAA news- STAAR Surgical (STAA) Q3 2026 Earnings Call TranscriptNasdaq
- Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue EstimatesNasdaqSTAA, CAH
- STAAR Surgical Reports Third Quarter 2026 ResultsBusiness Wire
- Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to DeclineNasdaqSTAA, HSIC
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)PR Newswire
- STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026Business Wire
- Why Staar Surgical Zoomed Almost 8% Higher on TuesdayNasdaqSTAA, SF
- After-Hours Earnings Report for August 12, 2026 : CSCO, COHR, PAAS, CAE, STN, ENS, REZI, TBBB, PLGO, HLIT, STAA, ENVXNasdaqCSCO, COHR, PAAS, CAE
STAAR Surgical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EYENational Vision Holdings Inc. | 16.72 | -1.70% | $1.31B | vs STAA |
| RXSTRxSight Inc. | 4.47 | -3.04% | $187.42M | vs STAA |
| LUCYInnovative Eyewear Inc. | 0.7025 | -0.07% | $6.12M | vs STAA |
| WRBYWarby Parker Inc. Class A | 23.12 | -4.19% | $2.87B | vs STAA |
| BLCOBausch + Lomb Corporation | 19.38 | -6.33% | $6.93B | vs STAA |
| COOThe Cooper Companies Inc. | 58.88 | -2.40% | $11.20B | vs STAA |
| ALCAlcon Inc. | 74.31 | -0.26% | $35.70B | vs STAA |
Indexes, lists and sector
STAAR Surgical stock FAQ
What is STAAR Surgical's stock price today?
STAA last traded at $24.22 as of Nov 20, 4:00 PM EST, down 3.24% on the day. Prices are delayed at least 15 minutes.
Does STAAR Surgical pay a dividend?
No. STAAR Surgical does not currently pay a regular cash dividend.
What is STAA's P/E ratio?
STAA trades at a trailing P/E ratio of 2422.00 and a forward P/E of 21.39, compared with a median of 20.4 for its closest peers.
Who is STAAR Surgical's CEO?
Mr. Warren Foust is the chief executive officer of STAAR Surgical Company, which has about 921 employees.
Has STAA ever split its stock?
Yes. The most recent STAA stock split was a 1-for-2 split on May 18, 1992.
What is the STAA 52-week high?
The 52-week high for STAA is $35.87 and the 52-week low is $15.59. The stock is currently 32.5% below its high.